

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on Monday 6th November 2023, I am pleased to confirm the following.

Patients with acute myeloid leukaemia (AML)

How many patients with AML, in total, have been treated with the following therapies during the last 6 months, irrespective of start date or line of therapy?

Azacitidine monotherapy
Low dose cytarabine (LoDAC) monotherapy
Venetoclax + azacitidine
Venetoclax + LoDAC
Ivosidenib
Intensive chemotherapy-based regimen
Other

Answer: 14

How many newly diagnosed patients with AML have started first-line treatment with the following therapies during the last 6 months?

Azacitidine monotherapy
Low dose cytarabine (LoDAC) monotherapy
Venetoclax + azacitidine
Venetoclax + LoDAC
Ivosidenib
Intensive chemotherapy-based regimen
Other

Note: this should only include patients who have started first-line treatment during the 6-month window

This is exempt under section 40 – personal information – this would involve search through patient medical records.

(a) Of the patients with AML treated with venetoclax (venetoclax + azacitidine or venetoclax + LoDAC) in the last 6 months, how many are approved for treatment via Blueteq?

Answer:8

Patients with chronic lymphocytic leukaemia (CLL)

How many patients with CLL have **received treatment** with venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Note: this should include patients who started treatment **prior** to the 6-month window

Answer: 12

How many patients with CLL who were **new to all lines of treatment** received venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Note: this should include only patients who have started treatment **during** the 6-month window

This is exempt under section 40 – personal information – this would involve search through patient medical records.

Please be advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom of Information Co-ordinator
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the
'Re-use of Public Sector Information Regulations' and best practice.